Abstract 815: Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer
Ping-Ching Hsu(University of Arkansas for Medical Sciences), Issam Makhoul(University of Arkansas for Medical Sciences), Susan Kadlubar(University of Arkansas for Medical Sciences), Eric R. Siegel(University of Arkansas for Medical Sciences), Valentina K. Todorova(University of Arkansas for Medical Sciences), Lora J. Rogers(University of Arkansas for Medical Sciences), Joseph Su(The University of Texas Southwestern Medical Center)
Cited by 0
Related Papers
Towards quality assurance and quality control in untargeted metabolomics studies
|Metabolomics|2019|149
Dietary Antioxidants and Prostate Cancer: A Review
|Nutrition and Cancer|2013|89
<i>In vitro</i> and <i>in vivo</i> oxidative metabolism and glucuronidation of anastrozole
|British Journal of Clinical Pharmacology|2010|79
Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).
|Journal of Clinical Oncology|2020|68
Survival outcomes of organ sparing surgery, partial penectomy, and total penectomy in pathological T1/T2 penile cancer: Report from the National Cancer Data Base
|Urologic Oncology Seminars and Original Investigations|2017|46